Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed Analysis.
Henrik WatzKathleen RickardTara RheaultThomas BengtssonDave SinghPublished in: International journal of chronic obstructive pulmonary disease (2020)
In these analyses, ensifentrine demonstrated a notable early and meaningful effect on dyspnea, with this effect observed across two different assessment tools.